Golimumab Treats RA When Other TNF-Alpha Inhibitors Fail (CME/CE)
June 30th, 2009 Posted by: admin
SAN FRANCISCO (MedPage Today) — Golimumab (Simponi) alleviates rheumatoid arthritis symptoms in patients who have previously received another tumor necrosis factor-alpha inhibitor, researchers found.
Similar Posts:
- Golimumab Treats RA When Other TNF-Alpha Inhibitors Fail (CME/CE)
- Golimumab Treats RA When Other TNF-Alpha Inhibitors Fail (CME/CE)
- Investigational Anti-TNF Biologic Modestly Helpful in Psoriatic Arthritis (CME/CE)
- Smoking Boosts Genetic Risk for Rheumatoid Arthritis (CME/CE)
- Anti-TNF Therapies Carry Varying Levels of TB Risk (CME/CE)
- Anti-TNF Therapies Carry Varying Levels of TB Risk (CME/CE)
- Anti-TNF Therapies Carry Varying Levels of TB Risk (CME/CE)
- Anti-TNF Therapies Carry Varying Levels of TB Risk (CME/CE)
- Anti-TNF Therapies Carry Varying Levels of TB Risk (CME/CE)
- EULAR: Early Rituximab Improves RA Response (CME/CE)